Yeping Wu

Yeping Wu

Auto-generated profile, based on publicly available information

Yeping Wu

Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
RPRobert G. Parton
Robert G. Parton
KMKerrie-Ann McMahon
Kerrie-Ann McMahon
YWYeping Wu
Yeping Wu

17 August 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YCYing Chen
Ying Chen
DWDan-Dan Wang
Dan-Dan Wang
YWYe-Ping Wu
Ye-Ping Wu
DSDan Su
Dan Su
TZTian-Yi Zhou
Tian-Yi Zhou
BYBo Yang
Bo Yang
Metastasis accounts for the most lethal reason for the death of ovarian cancer patients, but remains largely untreated. Epithelial–mesenchymal transition (EMT) is critical for the conversion of early-stage ovarian tumours into metastatic malignancies. Thus the exploration of the signalling pathways promoting EMT would open potential opportunities for the treatment of metastatic ovarian cancer. Herein, the putative role of MDM2 in regulating EMT and metastasis of ovarian cancer SKOV3 cells was investigated. The regulatory effects by MDM2 on cell motility was emulated by wound-healing and transwell assays. The effects on EMT transition and Smad pathway were studied by depicting the expression levels of epithelial marker E-cadherin as well as key components of Smad pathway. To evaluate the clinical relevance of our findings, the correlation of MDM2 expression levels with the stages of 104 ovarian cancer patients was investigated by immunohistochemistry assay. We demonstrate that MDM2 functions as a key factor to drive EMT and motility of ovarian SKOV3 cells, by facilitating the activation of TGF-β-Smad pathway, which results in the increased transcription of snail/slug and the subsequent loss of E-cadherin levels. Such induction of EMT is sustained in either E3 ligase-depleted MDM2 or E3 ligase inhibitor HLI-373-treated cells, while being impaired by the N-terminal deletion of MDM2, which is also reflected by the inhibitory effects against EMT by Nutlin-3a, the N-terminal targeting agent. The expression levels of MDM2 is highly correlated with the stages of the ovarian cancer patients, and the higher expression of MDM2 together with TGFB are closely correlated with poor prognosis and predict a high risk of ovarian cancer patients. This study suggests that MDM2 activates Smad pathway to promote EMT in ovarian cancer metastasis, and targeting the N-terminal of MDM2 can reprogram EMT and impede the mobility of cancer cells.

22 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKerrie-Ann McMahon
Kerrie-Ann McMahon
YWYeping Wu
Yeping Wu
YGYann Gambin
Yann Gambin
Emma SiereckiEmma Sierecki
Emma Sierecki
VTVikas A. Tillu
Vikas A. Tillu
RPRobert G. Parton
Robert G. Parton
Caveolae are specialized domains of the plasma membrane. Formation of these invaginations is dependent on the expression of Caveolin-1 or -3 and proteins of the cavin family. In response to stress, caveolae disassemble and cavins are released from caveolae, allowing cavins to potentially interact with intracellular targets. Here, we describe the intracellular (non-plasma membrane) cavin interactome using biotin affinity proteomics and mass spectrometry. We validate 47 potential cavin-interactor proteins using a cell-free expression system and protein-protein binding assays. These data, together with pathway analyses, reveal unknown roles for cavin proteins in metabolism and stress signaling. We validated the interaction between one candidate interactor protein, protein phosphatase 1 alpha (PP1α), and Cavin-1 and -3 and show that UV treatment causes release of Cavin3 from caveolae allowing interaction with, and inhibition of, PP1α. This interaction increases H2AX phosphorylation to stimulate apoptosis, identifying a pro-apoptotic signaling pathway from surface caveolae to the nucleus.

2 September 2020 in Autophagy
Verified
Journal Article
Closed access
NANick Ariotti
Nick Ariotti
YWYeping Wu
Yeping Wu
SOSatomi Okano
Satomi Okano
YGYann Gambin
Yann Gambin
JFJordan Follett
Jordan Follett
RPRobert G. Parton
Robert G. Parton
CAV1 (caveolin 1) expression and secretion is associated with prostate cancer (PCa) disease progression, but the mechanisms underpinning CAV1 release remain poorly understood. Numerous studies have shown CAV1 can be secreted within exosome-like vesicles, but antibody-mediated neutralization can mitigate PCa progression; this is suggestive of an inverted (non-exosomal) CAV1 topology. Here we show that CAV1 can be secreted from specific PCa types in an inverted vesicle-associated form consistent with the features of bioactive CAV1 secretion. Characterization of the isolated vesicles by electron microscopy, single-molecule fluorescence microscopy and proteomics reveals they represent a novel class of exosomes ~40 nm in diameter containing ~50-60 copies of CAV1 and, strikingly, are released via a non-canonical secretory macroautophagy/autophagy pathway. This study provides novel insights into a mechanism whereby CAV1 translocates from a normal plasma membrane distribution to an inverted secreted form implicated in PCa disease progression.

28 February 2023 in Developmental Cell
Verified
Journal Article
Closed access
YWYeping Wu
Yeping Wu
YLYe-Wheen Lim
Ye-Wheen Lim
DSDavid A. Stroud
David A. Stroud
NMNick Martel
Nick Martel
THThomas E. Hall
Thomas E. Hall
RPRobert G. Parton
Robert G. Parton

1 January 2014 in Cancer Letters
Verified
Journal Article
Closed access
YWYeping Wu
Yeping Wu
YFYingying Fu
Yingying Fu
LZLin Zheng
Lin Zheng
GLGuanyu Lin
Guanyu Lin
JMJian Ma
Jian Ma
BYBo Yang
Bo Yang